Latest Sickle-cell disease Stories
Extension Study Will Provide Data on Repeat Exposure to Vepoloxamer SAN DIEGO, May 26, 2015 /PRNewswire/ -- Mast
Changing a single letter of the human red blood cell DNA could be the key to curing sickle-cell anemia and other blood disorders.
Development Decision Leverages Recent Data with New ZFN-mediated Genome Editing Approach for Both Sickle Cell Disease and Beta-Thalassemia Programs RICHMOND, Calif., May 13, 2015 /PRNewswire/
SAN DIEGO, May 11, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical
On Track for Top-Line Data in Q1 2016 SAN DIEGO, April 21, 2015 /PRNewswire/ -- Mast Therapeutics, Inc.
Novel Product Focused On Treatment of Comorbidities of Sickle Cell Disease SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- Prolong Pharmaceuticals, LLC, a biopharmaceutical company
Rountree Brady Insurance Agency is starting a local charity program in the Savannah, GA area to help a 16-year-old boy currently struggling to keep up with his education due to hospital visits
SAN DIEGO, March 24, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical
Researchers at Johns Hopkins have successfully corrected a genetic error in stem cells from patients with sickle cell disease, and then used those cells to grow mature red blood cells, they report. The study represents an important step toward more effectively treating certain patients with sickle cell disease who need frequent blood transfusions and currently have few options.
The Georgia Health Policy Center (GHPC) at Georgia State University has received a five-year, $2,669,903 award from the U.S.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).